Moderna Cuts R&D by $1.1B, Focus on Key Approvals
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
- Latest
- Trending
Moderna shares dip as R&D spending reduces, focusing on FDA approval for 10 key products including RSV and cancer treatments.
Moderna & Coursera launch a free course on mRNA tech, transforming STEM education and workforce readiness globally.
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
Teladoc Health's revenue grew by 8% to $2.6 billion in 2023, with a gross margin of 70.8%. On the other ...
Pfizer and Moderna have struggled in the stock market, but Pfizer has a substantial pipeline of programs. Moderna's success is ...
The Third International Biotechnology Conference at Misr University for Science and Technology aims to address environmental and health challenges.
GSK and Elegen partner to develop new vaccines and medicines, harnessing Elegen's DNA manufacturing technology. Collaboration aims to expand genetic ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.